Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | TPMT | P51580 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6525079 | 0.98 | KMO (0.50) | KMOLMNAALOX15TSHRHIF1A | |
| Formamide SCHEMBL29197284 | 0.90 | LMNA (0.47) | KMOLMNAALOX15TSHRHIF1A | |
| SCHEMBL7878295 | 0.88 | LMNA (0.62) | KMOLMNAALOX15TSHRHIF1A | |
| SCHEMBL1179028 | 0.83 | ALDH1A1 (0.55) | KMOLMNAALOX15TSHRHIF1A | |
| SCHEMBL5683134 | 0.82 | LMNA (0.50) | KMOLMNAALOX15TSHRGPR35 | |
| Bicarbonate SCHEMBL10635309 | 0.80 | LMNA (0.46) | KMOLMNAALOX15TSHRHIF1A | |
| SCHEMBL113130 | 0.80 | LMNA (0.48) | KMOLMNAGPR35ALDH1A1MAPK1 | |
| SCHEMBL3659442 | 0.80 | LMNA (0.79) | KMOLMNAS1PR2 | |
| SCHEMBL15063590 | 0.78 | LMNA (0.52) | KMOLMNAALOX15TSHRHIF1A | |
| SCHEMBL9196203 | 0.78 | KMO (0.54) | KMOLMNAALOX15TSHRHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023040830-A1 | AHR INHIBITOR, USE THEREOF, AND PREPARATION METHOD THEREFOR | 北京华森英诺生物科技有限公司 | 2023-03-23 | — | — | WO | claimed |
| US-12612387-B2 | RAS inhibitors and methods of using the same | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2026-04-28 | — | — | US | disclosed |
| US-20250382283-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | NANJING IMMUNOPHAGE BIOTECH CO LTD (CN) | 2025-12-18 | — | — | US | disclosed |
| US-20250270201-A1 | SUBSTITUTED PYRIMIDINYL HYDRAZIDE COMPOUND AND PREPARATION METHOD AND USE THEREOF | ARIGENX THERAPEUTICS CO., LTD. (CN) | 2025-08-28 | — | — | US | disclosed |
| EP-4497747-A1 | SUBSTITUTED PYRIMIDINE HYDRAZIDE COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | Arigenx Therapeutics Co., Ltd. (CN) | 2025-01-29 | — | — | EP | disclosed |
| US-20240327386-A1 | AHR INHIBITOR, USE THEREOF, AND PREPARATION METHOD THEREFOR | CHONGQING PHARSCIN INNOBIO CO., LTD. (CN) | 2024-10-03 | — | — | US | disclosed |
| US-20240254113-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2024-08-01 | — | — | US | disclosed |
| CN-117715897-A | Compounds and their use as CD38 inhibitors | 南京艾美斐生物医药科技有限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-117003730-A | Substituted pyrimidine hydrazide compound and preparation method and application thereof | 德明药泰生物技术（深圳）有限公司 | 2023-11-07 | — | — | CN | disclosed |
| WO-2023208018-A1 | SUBSTITUTED PYRIMIDINE HYDRAZIDE COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | 德明药泰生物技术（深圳）有限公司 | 2023-11-02 | — | — | WO | disclosed |
| EP-0996617-B1 | 2,4-Dithi(oxo)-pyridin-5-yl compounds bearing a tricyclic substituent useful as P2 purinoceptor antagonists | ASTRAZENECA AB (SE) | 2002-01-09 | — | — | EP | disclosed |
| EP-1077981-A1 | NOVEL CEPHALOSPORIN COMPOUNDS, PROCESSES FOR PREPARATION THEREOF AND ANTIMICROBIAL COMPOSITIONS CONTAINING THE SAME | LG CHEMICAL LIMITED (KR) | 2001-02-28 | — | — | EP | disclosed |
| US-6107297-A | 2,4-Dithi(oxo)-pyrimidin-5-yl compounds bearing a tricyclic substituent useful as P2 purinoceptor antagonists | ASTRA PHARMACEUTICALS LIMITED (GB) | 2000-08-22 | — | — | US | disclosed |
| EP-0996617-A1 | NOVEL COMPOUNDS | Astra Pharmaceuticals Limited (GB) | 2000-05-03 | — | — | EP | disclosed |
| WO-1999058535-A1 | NOVEL CEPHALOSPORIN COMPOUNDS, PROCESSES FOR PREPARATION THEREOF AND ANTIMICROBIAL COMPOSITIONS CONTAINING THE SAME | LG CHEMICAL LTD. (KR) | 1999-11-18 | — | — | WO | disclosed |
| WO-1999002501-A1 | NOVEL COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1999-01-21 | — | — | WO | disclosed |
| US-4534908-A | Water-soluble disazo compounds and new bis-(aminophenoxy)-ethane compounds having fiber-reactive groups as the tetrazo components, and use of the disazo compounds as dyestuffs | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-08-13 | — | — | US | disclosed |
| EP-0071168-B1 | WATER-SOLUBLE DISAZO COMPOUNDS AND BIS-(AMINO-PHENOXY)-ETHANE COMPOUNDS WITH FIBRE REACTIVE GROUPS AS TETRAZO COMPOUNDS, PROCESS FOR THE PREPARATION OF THESE COMPOUNDS AND THE USE OF THE DISAZO COMPOUNDS AS DYESTUFFS | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-01-30 | — | — | EP | disclosed |
| US-4394310-A | DIAZOTIZATION, CYCLIZATION | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-07-19 | — | — | US | disclosed |
| EP-0071168-A2 | Water-soluble disazo compounds and bis-(amino-phenoxy)-ethane compounds with fibre reactive groups as tetrazo compounds, process for the preparation of these compounds and the use of the disazo compounds as dyestuffs | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327386-A1 | AHR INHIBITOR, USE THEREOF, AND PREPARATION METHOD THEREFOR | AHR, ARNT, AIPL1 | KMO 372/4885LMNA 3754/4885ALOX15 282/4885 |
| US-20250270201-A1 | SUBSTITUTED PYRIMIDINYL HYDRAZIDE COMPOUND AND PREPARATION METHOD AND USE THEREOF | AHR, ARNT, PAH | KMO 545/4885LMNA 4406/4885ALOX15 1754/4885 |
| US-12612387-B2 | RAS inhibitors and methods of using the same | KRAS, NRAS, HRAS | KMO 4604/4885LMNA 3438/4885ALOX15 3893/4885 |
| US-20240254113-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | CD38, CD22, BCL6B | KMO 3914/4885LMNA 518/4885ALOX15 703/4885 |
| US-20250382283-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | CD38, FCGRT, CD22 | KMO 2955/4885LMNA 1234/4885ALOX15 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.